Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
EMPLICITI vs POTELIGEO
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Elotuzumab is a humanized monoclonal antibody that targets the SLAMF7 (signaling lymphocytic activation molecule F7) receptor expressed on myeloma cells and natural killer (NK) cells. It enhances NK cell-mediated antibody-dependent cellular cytotoxicity (ADCC) via direct activation of NK cells through SLAMF7 and CD16 engagement, and also directly activates NK cells to induce killing of myeloma cells.
Mogamulizumab is a defucosylated humanized anti-CCR4 monoclonal antibody that binds to CCR4 on the surface of cells, inducing antibody-dependent cellular cytotoxicity (ADCC) and depleting CCR4-expressing cells, including malignant T cells and regulatory T cells (Tregs).
FDA-approved: In combination with lenalidomide and dexamethasone for the treatment of adult patients with multiple myeloma who have received one to three prior therapies,FDA-approved: In combination with pomalidomide and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor
Adult patients with relapsed or refractory mycosis fungoides (MF) or Sézary syndrome (SS) after at least one prior systemic therapy
10 mg/kg IV weekly for first 8 weeks, then every 2 weeks thereafter; administer with lenalidomide and dexamethasone.
3 mg/kg intravenously over 60 minutes on days 1, 8, and 15 of each 28-day cycle.
Terminal elimination half-life is approximately 26-29 days. This long half-life supports biweekly IV dosing after initial weekly schedule.
Terminal elimination half-life is approximately 17 days (range 11–22 days) at steady state, supporting every-2-week or every-4-week dosing intervals.
Elotuzumab is a monoclonal antibody; metabolism involves catabolism via proteolytic degradation into small peptides and amino acids. No specific CYP450 enzyme involvement.
Mogamulizumab is a monoclonal antibody; metabolism is via catabolic pathways into small peptides and amino acids. No specific metabolic enzymes identified.
Empliciti (elotuzumab) is a monoclonal antibody; elimination occurs via intracellular catabolism, yielding amino acids. Renal excretion of intact drug is negligible (<1%). Biliary/fecal excretion is minimal; no specific data on percentage.
POTELIGEO (mogamulizumab) is a monoclonal antibody, primarily eliminated via intracellular catabolism into amino acids. No quantitative data on renal or biliary excretion; minimal to no excretion as intact antibody in urine or feces.
Elotuzumab is a monoclonal antibody; protein binding is not clinically meaningful. Typically, monoclonal antibodies have negligible binding to plasma proteins other than target antigen.
Approximately 95% bound to plasma proteins, predominantly to immunoglobulins and albumin as a therapeutic monoclonal antibody.
Volume of distribution is approximately 5-7 L (or ~0.07 L/kg for a 70 kg patient), indicating distribution primarily in the vascular space.
Volume of distribution at steady state (Vss) is approximately 5.1 L (range 3.8–6.7 L), indicative of limited extravascular distribution, consistent with a monoclonal antibody primarily confined to vascular and interstitial spaces.
Empliciti is administered intravenously, thus bioavailability is 100% by IV route. No other routes are approved.
Only intravenous administration; intravenous bioavailability is 100% by definition.
No dose adjustment required for mild to moderate renal impairment (Cr Cl ≥30 m L/min). Not studied in severe renal impairment (Cr Cl <30 m L/min) or dialysis.
No dose adjustment required for mild to moderate renal impairment (Cr Cl 30-89 m L/min). Insufficient data for severe renal impairment (Cr Cl <30 m L/min) or dialysis.
No formal studies in hepatic impairment. Use caution in patients with moderate to severe hepatic impairment (Child-Pugh B or C) as exposure may be increased.
No dose adjustment required for Child-Pugh A or B. Insufficient data for Child-Pugh C. Use with caution.
Safety and efficacy not established in pediatric patients.
Safety and effectiveness not established in pediatric patients.
No specific dose adjustment required; monitor for toxicity due to age-related comorbidities and potential decreased organ function.
No specific dose adjustment recommended. Monitor for adverse effects more frequently due to potential age-related renal and hepatic function decline.
None
WARNING: DERMATOLOGIC TOXICITY. Severe, including fatal, dermatologic adverse reactions (e.g., Stevens-Johnson syndrome, toxic epidermal necrolysis) have occurred. Discontinue for suspected severe cutaneous adverse reactions.
Infusion reactions: Premedicate with acetaminophen, H1 and H2 blockers, and corticosteroids; monitor during infusion; may require interruption or discontinuation,Infections: Increased risk, especially with lymphopenia; monitor for signs and manage promptly,Second primary malignancies: Observed in clinical trials; consider risk,Hepatotoxicity: Elevations in liver enzymes; monitor hepatic function,Interference with serum protein electrophoresis and immunofixation assays: Elotuzumab may produce a band that interferes with detection of M-protein; monitor using alternative methods
Infusion reactions: Monitor during infusion; interrupt or discontinue based on severity.,Dermatologic toxicity: Severe skin reactions including SJS/TEN; discontinue if suspected.,Immune-mediated adverse reactions: including pneumonitis, hepatitis, colitis, endocrinopathies, and others.,Infections: Fatal infections occurred; monitor for infections and treat promptly.,Autoimmune hemolytic anemia: Fatal cases reported.,Posterior reversible encephalopathy syndrome (PRES): Discontinue if suspected.,Hematologic toxicity: Monitor blood counts; severe neutropenia, thrombocytopenia, and anemia reported.,Embryo-fetal toxicity: Can cause fetal harm; advise effective contraception.
History of severe hypersensitivity reactions to elotuzumab or any of its excipients
None
No specific food interactions with Empliciti have been identified. However, when used in combination with lenalidomide and dexamethasone, patients should avoid grapefruit and grapefruit juice due to potential interaction with lenalidomide metabolism (CYP3A4). Maintain adequate hydration and nutrition as tolerated.
No known food interactions. Grapefruit or other CYP inhibitors/inducers are not expected to affect mogamulizumab as it is a monoclonal antibody cleared via proteolysis. No dietary restrictions necessary.
Pregnancy Category N (not classified). Empliciti (elotuzumab) is a monoclonal antibody. Ig G molecules cross the placenta, with increasing transfer in the second and third trimesters. Based on its mechanism of action (SLAMF7-directed immunostimulatory), there is potential for fetal harm including B-cell depletion and immune alterations. No adequate human data; animal studies have not been conducted. Avoid use during pregnancy unless benefit outweighs risk.
POTELIGEO (mogamulizumab) is a monoclonal antibody. Ig G antibodies cross the placenta increasingly after the first trimester, with peak transfer in the third trimester. Based on its mechanism of action (CCR4-directed cytolytic activity), there is potential for fetal harm, including depletion of maternal and fetal T-cell subsets, especially regulatory T cells, which are critical for immune tolerance. Animal studies have not been conducted, but given the pharmacodynamics, use during pregnancy should be avoided unless clearly necessary. First trimester exposure carries theoretical risks of altered immune development; second and third trimester exposure may cause fetal lymphopenia and increased infection risk.
No data on presence in human milk, effects on breastfed infant, or milk production. Human Ig G is excreted in breast milk but not systemically absorbed in significant amounts. M/P ratio unknown. Consider developmental and health benefits of breastfeeding along with maternal need for therapy and potential adverse effects on infant (B-cell depletion).
It is unknown whether mogamulizumab is excreted in human milk. Human Ig G is present in breast milk, but concentrations are generally low. The M/P ratio has not been determined. Due to the potential for serious adverse reactions in the breastfed infant (e.g., immunosuppression), women should not breastfeed during treatment and for at least 5 half-lives (approximately 5 weeks) after the last dose.
No pharmacokinetic data in pregnancy. Monoclonal antibodies may have altered clearance due to increased plasma volume. However, no recommended dose adjustment; use with caution. No specific guidelines for dose modification during pregnancy.
No pharmacokinetic studies in pregnancy. Dosing adjustments are not established; however, physiologic changes in pregnancy (e.g., increased plasma volume, altered clearance) may affect pharmacokinetics. Given the monoclonal antibody, no dose adjustment is recommended, but clinical monitoring for efficacy and toxicity should be considered. Use only if potential benefit justifies potential risk.
Empliciti (elotuzumab) is an immunostimulatory monoclonal antibody used in combination with lenalidomide and dexamethasone for relapsed/refractory multiple myeloma. Premedicate with diphenhydramine, acetaminophen, and H2 blocker to mitigate infusion reactions (IRs). Monitor for IRs, notably hypotension, bronchospasm, and urticaria, especially during the first dose. Administer corticosteroids prior to empliciti infusion to reduce IR risk. Do not administer as an intravenous push or bolus; use a controlled intravenous infusion. If a dose is missed, administer as soon as possible; do not wait until the next scheduled dose. Empliciti carries a boxed warning for increased mortality when used with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma who are not candidates for transplant. Advise patients of potential teratogenicity with lenalidomide and dexamethasone; ensure pregnancy prevention.
Poteligeo (mogamulizumab) is a humanized anti-CCR4 monoclonal antibody used for adult T-cell leukemia-lymphoma (ATLL) and mycosis fungoides (MF)/Sézary syndrome (SS). It depletes CCR4-expressing T cells, including regulatory T cells (Tregs), which may exacerbate graft-versus-host disease (GVHD) after transplant. Monitor for infusion reactions and severe cutaneous adverse reactions (e.g., Stevens-Johnson syndrome). Dose reduction for creatinine clearance <30 m L/min is not established; avoid in severe renal impairment. Premedicate with antihistamines and acetaminophen. Live vaccines contraindicated during and after treatment.
You will receive Empliciti as an intravenous infusion over several hours, and you will be monitored for infusion reactions such as chills, fever, difficulty breathing, or rash.,Before each infusion, you will receive medicines to reduce the risk of infusion reactions, including acetaminophen, an antihistamine, and a corticosteroid.,If you miss an appointment, contact your healthcare provider immediately to reschedule; do not wait until the next scheduled dose.,Empliciti may cause serious infections; report any signs of infection such as fever, cough, or pain.,Avoid pregnancy while on Empliciti combination therapy; use effective contraception and discuss appropriate methods with your doctor.,You may experience fatigue, diarrhea, constipation, or nerve pain; inform your doctor if these become bothersome.
Poteligeo can cause severe skin reactions; report any rash, blisters, or peeling skin immediately.,You may experience infusion reactions (fever, chills, nausea) during or after infusion; premedication will be given.,Avoid live vaccines (e.g., MMR, varicella) during treatment and for at least 1 year after last dose.,Do not breastfeed while on Poteligeo and for at least 2 months after last dose.,Use effective birth control during treatment and for at least 3 months after last dose.,Notify your doctor if you have a history of organ transplant or are planning a transplant.,Poteligeo can lower your immune system; report signs of infection (fever, cough, sore throat).
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about EMPLICITI vs POTELIGEO, answered by our medical review team.
EMPLICITI is a Monoclonal Antibody Antineoplastic that works by Elotuzumab is a humanized monoclonal antibody that targets the SLAMF7 (signaling lymphocytic activation molecule F7) receptor expressed on myeloma cells and natural killer (NK) cells. It enhances NK cell-mediated antibody-dependent cellular cytotoxicity (ADCC) via direct activation of NK cells through SLAMF7 and CD16 engagement, and also directly activates NK cells to induce killing of myeloma cells.. POTELIGEO is a Monoclonal Antibody Antineoplastic that works by Mogamulizumab is a defucosylated humanized anti-CCR4 monoclonal antibody that binds to CCR4 on the surface of cells, inducing antibody-dependent cellular cytotoxicity (ADCC) and depleting CCR4-expressing cells, including malignant T cells and regulatory T cells (Tregs).. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between EMPLICITI and POTELIGEO depend on the specific clinical indication. These are both Monoclonal Antibody Antineoplastic agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of EMPLICITI is: 10 mg/kg IV weekly for first 8 weeks, then every 2 weeks thereafter; administer with lenalidomide and dexamethasone.. The standard adult dose of POTELIGEO is: 3 mg/kg intravenously over 60 minutes on days 1, 8, and 15 of each 28-day cycle.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between EMPLICITI and POTELIGEO in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. EMPLICITI is classified as Category C. Pregnancy Category N (not classified). Empliciti (elotuzumab) is a monoclonal antibody. IgG molecules cross the placenta, with increasing transfer in the second and third trimester. POTELIGEO is classified as Category C. POTELIGEO (mogamulizumab) is a monoclonal antibody. IgG antibodies cross the placenta increasingly after the first trimester, with peak transfer in the third trimester. Based on it. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.